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Practical aspects of hormonal therapy for localized prostate cancer
Patricia Tai
In the past, hormonal therapy was only used for the treatment of metastatic prostatic cancer, but it has now assumed an
increasingly important role in the management of intermediate and high risk localized prostate cancer as neoadjuvant or
adjuvant treatment. It also has a role in treatment of local or distant failure after radiation. This review summarises the recent
developments and the issues to be explored in the future: from chemoprevention to treatment. 5-alpha-reductase inhibition using
drugs such as finasteride have been shown to decrease androgenic stimulation of the prostate and currently being tested in
chemoprevention trials. Bilateral orchiectomy has been regarded as the gold standard of therapy, to which other treatments are
compared. Most published studies showed no extra benefit of total androgen blockade (TAB) over monotherapy. TAB
results in more hot flushes, fatigue, bone and joint pain, osteoporosis and fracture, anaemia, impotence. Anti-androgens do
not seem to affect sexual function, physical capacity, strength and vitality as much. However gynaecomastia is more common
with monotherapy antiandrogen than TAB. When hormone is combined with radiotherapy in both RTOG 85-31 and RTOG
86-10 studies, statistically significant improvements in outcome were observed between the radiotherapy and hormones
combined (group I) and radiotherapy alone (group II) groups, when analysed for biochemical disease-free survival and distant
metastases failure. Currently another ongoing research area is the intermittent androgen deprivation approach, which is
meant to provide treatment to control the tumour, with a potential for prolonged therapy-free intervals resulting in improved
quality of life, delay in progression to androgen independence, and reduced cost of therapy.
Terapia hormonalna w miejscowo zaawansowanym raku prostaty – aspekty praktyczne
Terapia hormonalna, jeszcze niedawno stosowana tylko w rozsianym raku prostaty, staje si´ obecnie coraz wa˝niejszym ele-
mentem leczenia zlokalizowanego raka prostaty u chorych, tak ze Êrednim, jak i z wysokim ryzykiem. Bywa stosowana zarów-
no jako leczenie adiuwantowe, jak i neoadiuwantowe, ma równie˝ istotne znaczenie w leczeniu wznów miejscowych lub prze-
rzutów po radioterapii. Niniejsza praca poglàdowa ma na celu podsumowanie dotychczasowych post´pów leczenia hormo-
nalnego oraz nakreÊlenie perspektyw jego dalszego rozwoju od chemoprewencji do leczenia.
Dowiedziono, ˝e inhibitory 5-alfa-reduktazy, takie jak finasteryd, zmniejszajà stymulacj´ androgenicznà gruczo∏u krokowego.
Sà one obecnie poddawane ocenie w toku badaƒ nad chemoprewencjà. Jak dotychczas, za z∏oty standard w terapii hormo-
nalnej uznawano obustronnà orchidektomi´ – stanowi ona punkt odniesienia dla porównywania wyników innych form lecze-
nia hormonalnego. Niektóre publikowane badania nie wykaza∏y dodatkowych korzyÊci p∏ynàcych z ca∏kowitej blokady andro-
genowej (total androgen blockade – TAB), w porównaniu z monoterapià. Po ca∏kowitej blokadzie androgenowej chorzy cz´-
Êciej skar˝à si´ na uderzenia goràca, znu˝enie, bóle kostno-stawowe, osteoporoz´, z∏amania koÊci i impotencj´. Wydaje si´, ˝e
anty-androgeny nie wp∏ywajà w tak znacznym stopniu na aktywnoÊç seksualnà, sprawnoÊç fizycznà, si∏´ i witalnoÊç. Z drugiej
strony ginekomastia cz´Êciej towarzyszy monoterapii antyandrogenowej ni˝ ca∏kowitej blokadzie androgenowej. Badania prze-
prowadzone w celu oceny skutecznoÊci leczenia obejmujàcego po∏àczenie terapii hormonalnej z radioterapià (RTOG 85-31
i RTOG 86-10) wykaza∏y znamiennà statystycznie popraw´ wyników leczenia w toku terapii ∏àczonej, w porównaniu z lecze-
niem tylko radioterapià – oceniano wyk∏adniki biochemiczne prze˝ycia bez choroby oraz niepowodzenia leczenia pod posta-
cià odleg∏ych przerzutów. Inny kierunek badaƒ obejmuje przejÊciowe pozbawienie chorego wp∏ywu androgenów, co umo˝liwia
ograniczenie choroby i stwarza mo˝liwoÊç wyd∏u˝enia przerw w terapii antyandrogenowej, a w efekcie poprawia jakoÊç ˝ycia,
odwleka moment ca∏kowitej blokady androgenowej i zmniejsza koszty leczenia.
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Role of hormonal manipulation for 
chemoprevention
5-alpha-reductase inhibition using drugs such as
finasteride have been shown to decrease androgenic
stimulation of the prostate. In clinical studies, 5-alpha-
reductase inhibitors suppress serum and intraprostatic
levels of dihydrotestosterone, an important promoter of
prostate cancer, leading to reduction in prostate size and
suppression of glandular cell activity as measured
by PSA secretion [1]. In addition, 5-alpha-reductase
inhibitors have demonstrated an excellent safety profile
and tolerance in controlled clinical trials.
No significant metabolic effects have been observed
in gonadotropin secretion, spermatogenesis, serum lipids
or glucose tolerance. The efficacy and safety of 5-alpha-
reductase inhibitors in studies to date, combined with the
androgen dependence of tumour production, strongly
supports investigating their use for chemoprevention of
prostate cancer.
A SWOG clinical trial is underway using finasteride
to assess this hypothesis: the Prostate Cancer Prevention
Trial has completed randomisation of over 18,000 healthy
men, aged 55 and older, to either finasteride (5 mg/day)
or placebo to be taken for seven years [2]. The primary
objective of this study is to determine whether finasteride
can reduce the prevalence of prostate cancer over
a seven-year period [3].
Apart from finasteride, epidemiological and labora-
tory studies also suggest that those with high selenium
and vitamin E intake may lower the risk of prostate
cancer [4].
Choice of hormone
Experience of hormonal therapy for adjuvant or salvage
treatment is based on its effect on metastastic disease.
Prostate cancer responds to androgen hormonal ablation
with bilateral orchiectomy, an approach that is regarded
as the gold standard of therapy but not always the
preferred treatment of patients, due to psychological
impact of disfigurement and irreversibility. Oestrogen
therapy is an alternative but is associated with side effects,
such as hot flushes and gynaecomastia, which frequently
leads to treatment cessation. Luteinising hormone-
releasing hormone (LHRH) analogues work by initially
producing a surge of androgen, followed by a down-
regulation in hormone production to effect a medical
castration [5]. Various groups have studied the effects of
androgen blockade administered as monotherapy and as
combination therapy: LHRH analogue plus antiandrogen.
The National Cancer Institute intergroup protocol
0036, which is the largest cooperative study to date of
patients with advanced prostatic cancer, showed that
combination therapy with leuprolide and flutamide
offered greater benefit in both time to disease progression
and median survival while circumventing tumour flare
and its associated symptoms [6, 7]. The subgroup of good
performance status and minimal metastatic disease
showed particularly benefit from the total androgen
blockade versus leuprolide alone [8]. Thus, combination
therapy for total androgen ablation becomes an important
treatment option for adjuvant and salvage treatment.
However, some may choose to use monotherapy due to
expense, side effects and some published studies showing
no extra benefit to total androgen blockade (TAB) [9-11].
In a study 220 patients with either locally advanced
or disseminated prostate cancer were randomly assigned
to treatment with bicalutamide 150 mg daily or the
combination of flutamide 750 mg daily plus monthly
goserelin acetate injections. At a median follow-up time
of 38 months there was no difference in the duration of
either progression-free survival or overall survival. Median
time to progression was 25 months in the bicalutamide
group and 23 months in the TAB group. Median survivals
were 44 and 45 months respectively. Cancer specific
mortality rates were also comparable [12].
In the past, flutamide was the most common
monotherapy. Androcur (cyproterone acetate) was also
commonly used and this works both on the periphery and
central mechanism, so it is one form of TAB.
Nowadays more physicians are changing to use
Casodex (bicalutamide) because it has fewer side effects
and is less likely to cause hormone-resistance than
flutamide. An interesting publication on Casodex mono-
therapy showed that it is less effective than castration in
patients with metastatic disease with a difference in
median survival of six weeks [13]. However it has shown
a benefit in terms of quality of life and subjective response
when compared to castration and that it has an acceptable
tolerance profile.
TAB results in more hot flushes, fatigue, bone and
joint pain, osteoporosis, fracture, anaemia and impotence.
Anti-androgens do not seem to affect sexual function,
physical capacity, strength and vitality as much. However
gynaecomastia is more common with monotherapy
antiandrogen than TAB [14]. Diarrhoea, nausea and
asthenia were also more common in patients treated with
bicalutamide than in those treated with castration [14].
Among the different anti-androgens, flutamide tends
to cause more gastrointestinal upset and liver toxicity.
Nilutamide has a relatively high incidence of side effects,
including decreased adaptation to darkness, interstitial
pneumonitis, nausea, and alcohol intolerance. Bicaluta-
mide has a very low incidence of above side effects [14].
Hormonal therapy as primary treatment
Although it is not commonly used in the United States,
some patients in other countries may prefer this primary
treatment because of its convenience. The disadvantage is
that when the patient develops hormone resistance, it is
very difficult to justify the rationale of prescribing this
non-curative treatment.
The National Cancer Institute of Canada (NCIC
PR.3) has joined the Medical Research Council (MRC) of
United Kingdom in the INT T94-0110 trial. The trial is
ongoing and evaluates any benefit from the addition of
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radiation therapy to the treatment of patients with cancer
of the prostate who are receiving TAB in terms of overall
survival, time to progression, symptomatic local control
and quality of life.
Figure 1 shows a patient with a locally extensive
prostate cancer involving the bladder. Surprisingly he
only had mild urinary obstruction that was successfully
treated with transurethral resection. He declined radical
radiotherapy and preferred to have hormonal treatment
alone.
Hormonal therapy combined with surgery
There are studies both for and against the approach of
hormonal therapy combined with surgery. The Mayo
Clinic studied 22 patients with clinical stage B2 (T2c) or C
(T3) prostate cancer who underwent androgen depriva-
tion therapy before radical prostatectomy as part of
a down-staging protocol: group 1 cases [15]. The
concentration of serum PSA was determined before and
at the conclusion of androgen deprivation therapy, just
before operation. For each group 1 patient a matched
patient who had not received preoperative endocrine
therapy was chosen: group 2 cases.
The ages of both group 1 and 2 patients were similar
and the clinical stage of disease and pre-treatment tumour
grade in group 2 were identical to the stage and grade
in group 1. In addition, the serum PSA value in group 2
was similar to that of group 1 before initiation of
androgen deprivation therapy. In group 1 the median
serum PSA concentration was 14.8 ng/ml with a range of
3.1-99 ng/ml, before endocrine therapy and a median of
0.2 ng/ml with a range of 0.1-3.4 ng/ml, after hormonal
treatment. Group 2 cases had a median level of 13.3 ng/ml
and range of 3.4-100 ng/ml. The median decrease in the
serum PSA concentration for group 1 as a result of
androgen deprivation therapy was 98.5%. The radical
prostatectomy specimens from these two groups of similar
patients had no differences with regard to maximum
tumour dimension, pathological stage and deoxyribo-
nucleic acid ploidy status. These findings indicate that
serum PSA becomes an unreliable indicator of disease
status after initiating pre-operative androgen deprivation
therapy and that pre-operative androgen deprivation
therapy has little or no benefit for decreasing the extent of
tumour or pathological stage.
The observations in a different study showed more
difficulties and the blood loss was higher in patients who
had pre-operative hormonal deprivation [16]. This finding
is the opposite to the experience from Quebec [17] where
it was found that the volume of the prostate gland
decreased by approximately 48% as assessed by TRUS
and digital rectal examination after three months of
flutamide and a LHRH agonist. The atrophy of the
prostate gland markedly facilitated dissection of the
prostate from closely associated and vulnerable structures
such as the prostatic apex and the prostatic posterolateral
neurovascular bundle. Impressive down-staging effects
of the combination therapy on the histology of prostatic
tumours were observed, including the absence of
detectable cancer in 12/50 surgically removed prostate
glands. The median time for recovery of potency after
therapy was 7.5 months after cessation of the combination
therapy.
Hormonal therapy combined with radiotherapy
RTOG 85-31 and RTOG 86-10 studies examined the
questions of how long should hormonal therapy be given
and who will benefit from it. Patients were randomised
to receive long-term hormones (LTH) on RTOG 85-31
and received goserelin, continued indefinitely, but
starting the last week of external beam radiotherapy.
Patients treated with short-term hormones (STH) on
RTOG 86-10 received goserelin and flutamide two
months prior to and during radiotherapy. The median
follow-up for all patients was 71 months with a range of
0.6-129 months.
Combining both studies, statistically significant
improvements in outcome were observed between the
radiotherapy and hormones combined (group I) and
radiotherapy alone (group II) groups, when analysed for
biochemical disease-free survival (bNED control) and
distant metastases failure (DMF). Statistically significant
improvements in bNED control, DMF and cause-specific
failure (CSF) were observed for patients receiving LTH
compared with STH.
In those patients receiving LTH, the benefit in
bNED control (p=0.0002), DMF (p=0.05) and CSF
(p=0.02) was limited to centrally reviewed Gleason scores
of 7 and scores 8-10 for tumours. For all patients treated
on RTOG 85-31, statistically significant improvements
for bNED control, DMF, and CSF were observed
between groups I and II [18].
There is evidence for a benefit of hormonal therapy
when combined with brachytherapy, in a study with
similar subset of patients [19]. Low risk patients defined
by PSA 10 ng/ml, stage T2a, and Gleason score 6
Figure 1. CT scan showing a locally extensive prostate cancer involving
the bladder
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did not benefit from neoadjuvant hormonal therapy: 3.8%
versus 7.7% positive biopsy rate after treatment, p=0.5.
For the high risk patients, that is, the remainder of the
patients who did not belong to the low risk group, the
results were 3.4% versus 21.1%, p=0.003.
However, the duration of hormonal therapy is still
controversial: it can be given as a neoadjuvant treatment
and then extended after radiotherapy as an adjuvant
treatment. Bolla's study used a total duration of three
years [20] and the RTOG study 92-02 used it for two
years after external beam radiotherapy.
Salvage hormonal therapy for localised prostate
cancer
T i m i n g  o f  h o r m o n a l  t h e r a p y
The NCI study [8] suggested that early total androgen
blockade may be advantageous to delayed treatment for
patients with metastatic prostate cancer. An analogy may
be drawn between patients who have rising PSA after
failure of the primary treatment and it is possible that
early treatment may improve survival but we need
randomised trials to confirm this suggestion.
D e l i v e r y  o f  h o r m o n a l  t h e r a p y
Prostate cancer is an androgen-dependent tumour
and deprivation of androgen hormone has been the
mainstay in the management of patients with distant
metastases. Despite an initial response rate of about 80%,
predictable and irreversible resistance to androgen
deprivation will occur in the vast majority of patients.
This progression from initial response is attributed to the
fact that surviving tumour cells become androgen-
independent [21-23].
Currently there is increasing evidence suggesting
that progression to androgen-independence is an adaptive
process secondary to androgen withdrawal. In studying
mechanisms of progression, Bruchovsky found that, in
the androgen-dependent shionogi carcinoma model,
androgen withdrawal alters the ratio of stem cells in the
tumour cell population [24]. Initially there is an
elimination of differentiated cells and a decrease in the
proportion of tumourigenic stem cell. At the time of
progression and recurrence a marked 20-fold increase in
the proportion of total stem cells and 500-fold increase in
the proportion of androgen-independent stem cells was
noted. These data suggest that progression begins early in
the disease course secondary to lack of androgen-induced
differentiation of the parent stem cells with resultant loss
of apoptotic potential [24]. If androgens are replaced
before progression begins, the surviving stem cells should
give rise to an androgen-dependent tumour susceptible to
further hormonal manipulation.
Intermittent androgen deprivation therapy has been
studied in animal models. In the androgen-dependent
tumour models, investigators found that apoptosis could
be re-induced and that this approach prolonged, indeed
almost tripled, the mean time to androgen-independent
status [25-27].
Clinical data indicate that a satisfactory palliative
response can be achieved in patients who have restarted
androgen deprivation therapy following a period without
any therapy. Prolonged therapy-free intervals of several
months could be achieved without apparent adverse effect
on survival [25, 26]. This experience in metastatic disease
is utilised in the salvage treatment of rising PSA after
failure of the primary treatment. It is understood that
this salvage treatment is not curative but its use is justified
because many of these patients are elderly, and salvage
prostatectomy or brachytherapy or cryotherapy has severe
treatment morbidity.
In addition, despite the most advanced imaging
techniques, it is possible these patients may have
micrometastases in the lymph nodes or distant organs.
The intermittent androgen deprivation approach is meant
to provide treatment to control the tumour, with
a potential for prolonged therapy-free intervals resulting
in improved quality of life, delay in progression to
androgen independence, and reduced cost of therapy.
Additionally, the men in this study stand to gain relief
from distressing side effects and to regain potency.
The duration of induction therapy is crucial for the
success of this approach. The induction duration should
be the time required for maximal tumour suppression as
represented by PSA nadirs. Current data indicate that
50-80% of metastatic patients will achieve a nadir PSA by
3-8 months following hormonal therapy [28-30].
Since the benefits of intermittent androgen depriva-
tion therapy can only be appropriately evaluated in
a randomised fashion, a phase III intergrup study of the
National Cancer Institute of Canada (PR.7) and the
South-West Oncology Group (JPR-7) is now ongoing.
To t a l  a n d r o g e n  b l o c k a d e  o r  m o n o t h e r a p y
From the above discussion, one may question the value of
a total androgen blockade since the latter may give rise to
androgen-independent clones. Also, it is not clear from
literature if total androgen blockade is better than
monotherapy in terms of overall and progression-free
survival.
Conclusions
Hormonal therapy has been considered to be the standard
treatment at the time of cancer progression after
definitive therapy, and many of the randomised trials
have essentially compared adjuvant therapy to delayed
therapy. Historical trials using adjuvant hormonal therapy
have been limited due to difficulties in clinical staging, as
well as toxicities attributed to the formulations used.
More recently, hormonal therapy has been found to delay
disease progression, increase disease-free survival,
and decrease mortality when given immediately after
prostatectomy or radiation therapy in selected patients.
Neoadjuvant hormonal therapy can improve disease-free
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survival and local control when given before radiation
therapy; it has only decreased positive surgical margins
when given prior to radical prostatectomy but no
demonstrated survival benefit from studies to date.
Patricia Tai MD
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